Molecular imaging study reveals improved detection of early recurrent prostate cancer

September 17, 2015

A recently developed drug was significantly better at detecting recurring prostate cancer in early stages, in research published in the August 2015 issue of The Journal of Nuclear Medicine

In the study, the imaging agent—Ga-68 prostate-specific membrane antigen (Ga-68 PSMA)—used with positron emission tomography and computed tomography (PET/CT), changed management in 44% more cases than another widely used agent.

Read the full story.